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ABSTRACT
A better understanding of the dynamics of molecular changes occurring during 
the early stages of oral tumorigenesis may help refine prevention and treatment 
strategies. We generated genome-wide expression profiles of microdissected normal 
mucosa, hyperplasia, dysplasia and tumors derived from the 4-NQO mouse model 
of oral tumorigenesis. Genes differentially expressed between tumor and normal 
mucosa defined the “tumor gene set” (TGS), including 4 non-overlapping gene subsets 
that characterize the dynamics of gene expression changes through different stages 
of disease progression. The majority of gene expression changes occurred early or 
progressively. The relevance of these mouse gene sets to human disease was tested 
in multiple datasets including the TCGA and the Genomics of Drug Sensitivity in Cancer 
project. The TGS was able to discriminate oral squamous cell carcinoma (OSCC) from 
normal oral mucosa in 3 independent datasets. The OSCC samples enriched in the 
mouse TGS displayed high frequency of CASP8 mutations, 11q13.3 amplifications and 
low frequency of PIK3CA mutations. Early changes observed in the 4-NQO model were 
associated with a trend toward a shorter oral cancer-free survival in patients with 
oral preneoplasia that was not seen in multivariate analysis. Progressive changes 
observed in the 4-NQO model were associated with an increased sensitivity to 4 
different MEK inhibitors in a panel of 51 squamous cell carcinoma cell lines of the 
aerodigestive tract. In conclusion, the dynamics of molecular changes in the 4-NQO 
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model reveal that MEK inhibition may be relevant to prevention and treatment of a 
specific molecularly-defined subgroup of OSCC.
INTRODUCTION
Personalization of prevention strategies may allow 
the decrease of morbidity and mortality of head and 
neck squamous cell carcinoma (HNSCC), the second 
most common smoking-related cancer after lung cancer 
[1]. Previous reports on head and neck premalignancy 
and chemoprevention have focused on oral squamous 
cell carcinoma (OSCC), the most common anatomical 
site of HNSCC. Although prospective evaluations of 
chemopreventive agents have not yet resulted in the 
development of an intervention that can be considered 
as standard of care, they allowed the identification of 
new biomarkers of OSCC risk in patients with oral 
premalignant lesions (OPL), the most validated one being 
loss of heterozygosities (LOH) at various sites [2–4].
Despite those efforts, the natural history of OPL 
remains poorly understood, as they may persist for years, 
regress spontaneously or after tobacco or alcohol cessation, 
or evolve into invasive SCC in about 20% cases over periods 
of up to 30 years [5–8]. A comprehensive characterization 
of the molecular changes occurring in OPL may improve 
our understanding of their natural history [7–10]. We have 
previously shown that gene expression profiles of OPL may 
improve the prediction of oral cancer [11]. However, the 
study was limited to patients treated with retinoids and to 
the analysis of a single baseline biopsy, which did not allow 
us to appreciate the dynamics of gene expression changes 
over time.
In order to address these limitations and to identify 
key molecular changes leading to the development of 
cancer, we sought to characterize the dynamics of gene 
expression changes in the 4-nitroquinoline 1-oxide (4-NQO) 
mouse model of human oral carcinogenesis that leads to the 
development of malignant SCC preceded by preneoplastic 
histological changes such as hyperplasia and dysplasia [12–
16]. Progression of premalignant pathologic stages has been 
well described in this model [14], showing hyperplasia at first 
weeks after 4-NQO administration and then an increasing 
percentage of dysplasia and tumors, reproducing the 
multi-step tumor process observed in humans. This model 
represents a relevant model of human SCC as it is associated 
with genetic alterations similar to those observed with 
smoking exposure in HNSCC (i.e. EGFR overexpression) 
[13, 16]. However, the 4-NQO mouse model has not 
been extensively characterized at the molecular level.
In the present study, we characterized genome-
wide expression changes in the 4-NQO mouse model 
and identified gene sets specific of sequential histological 
changes and demonstrated the relevance of those changes 
in human OSCC. An integrative analysis of the TCGA data 
showed that the 4-NQO model may represent a specific 
molecularly-defined subgroup of OSCC, and may be 
associated with patterns of drug sensitivity in human in vitro 
models of aerodigestive SCC. The study of the dynamics of 
gene expression changes during oral tumorigenesis may help 
refine prevention and treatment strategies.
RESULTS
Dynamics of gene expression changes during 
oral tumorigenesis in the 4-NQO mouse model
Nine mice treated by the 4 NQO as described 
elsewhere [14] and three control mice (non-treated) were 
selected for transcriptomic analysis. Total RNA extraction 
was performed from microdissected epithelial cells of 
tongue mucosa, including 3 normal mucosa from control 
mice (week 12, 20, and 24), 3 hyperplastic lesions (1 
at week 16 and 2 at week 20), 3 dysplastic lesions (2 at 
week16, 1 at week 24) and 3 tumor samples (at week 16, 
20 and 24) from the 4-NQO treated mice (Figure 1A). 
Median RIN was 7.55 (range 4.6-9.2) with no significant 
difference between normal, hyperplastic, dysplastic and 
tumor samples. RNA concentration ranged between 0.5 
and 5.7 ng/μL, with a median of 1.2 ng/μL. All of the 12 
samples passed the quality controls, were amplified and 
arrays were hybridized on Mouse Gene ST 2.0 Arrays. The 
technical information is detailed in Supplementary Table 1.
A principal component analysis (PCA) of the 
12 samples using whole-genome expression profiles 
demonstrated strong patterns of normal mucosa, 
hyperplastic, dysplastic and tumors lesions as shown in 
Figure 1B. We then identified several sets of genes that 
were associated with histological changes (Figure 1A). 
Differential expression was defined by an absolute log2 
fold-change (FC) >1. Each gene set was divided into an 
“UP” version for genes upregulated (log2 FC > 1) and a 
down (DN) version for genes downregulated (log2 FC <-1), 
respectively. Five mouse gene sets were defined and human 
orthologous genes were identified for each gene set, using 
the JAX and HUGO orthology resources [17, 18]. We first 
identified a set of genes differentially expressed between 
tumor and normal mucosa that we called the “tumor gene 
set” (TGS). TGS included 584 and 753 mouse genes that 
were up- and down-regulated genes in tumors, respectively, 
and that correspond to 514 and 508 human orthologous 
genes respectively (Supplementary Table 2). A PCA of the 
12 samples using TGS demonstrated a similar pattern as 
the one observed using whole-genome expression profiles 
(Supplementary Figure 1A).
In order to capture the dynamics of gene expression 
changes during oral tumorigenesis, we subsequently 
divided the TGS set into four non-overlapping gene 
subsets: the “early” (EGS), the “intermediate” (IGS) and 
the “late” (LGS) gene subsets, which represented the 
changes observed at each step of oral tumorigenesis (i.e. 
hyperplasia vs. normal mucosa, dysplasia vs. hyperplasia 
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and tumor vs. dysplasia respectively). Genes included 
in EGS, IGS and LGS were differentially expressed at 
a given stage of oral tumorigenesis but not differentially 
expressed at any previous stage. The fourth gene subset, 
“progressive” gene set (PGS), represented changes 
acquired progressively during each step, that reached 
an absolute log2 FC > 1 in tumor vs. normal mucosa, 
but did not reach this FC at any individual steps of oral 
tumorigenesis (Supplementary Table 3). EGS and PGS 
included the largest number of genes (Supplementary 
Table 2). Details of the genes included in each gene set 
are provided in Supplementary Table 4.
In order to gain insight on the biological significance 
of genes differentially expressed in mice tumors vs. normal 
mucosa, a gene set enrichment analysis (GSEA) was 
performed to determine whether an a priori defined set of 
genes showed statistically significant differences between 
tumor vs normal samples [19]. The log2 FC was used to 
successively analyze a total of 4,722 “curated gene sets” 
(C2) and 189 “oncogenic signatures” (C6) available from 
the MSigDB [19]. The most significant gene sets with a 
positive enrichment score among “curated gene sets” were 
related to proliferation and cell cycle (Supplementary 
Figure 1B). EGFR and VEGF pathways were the most 
significantly enriched gene sets with a positive score, 
among the 189 “oncogenic signatures” (Supplementary 
Figure 1C).
We then used the single sample GSEA (ssGSEA) 
[19, 20] to compute an enrichment score (ES) for the 
four subsets (EGS, IGS, LGS and PGS) in each of the 12 
Figure 1: Dynamic gene expression changes during oral tumorigenesis in the 4-NQO mouse model and their association 
with canonical pathways. A. Histologic changes during oral carcinogenesis in the mouse model and corresponding gene set for each 
step of this tumor process: normal, hyperplastic, dysplastic and tumor mucosa. B. Principal component analysis including the 12 samples 
and using whole-genome. C. An enrichment rate was computed for early (EGS), intermediate (IGS), late (LGS) and progressive (PGS) 
gene sets at each step of oral tumorigenesis, i.e. between normal and hyperplasia (H-N), hyperplasia and dysplasia (D-H), and dysplasia 
and tumor (T-D) (see Material and Methods section). D. Enrichment scores for EGS, IGS, LGS and PGS gene subsets were correlated with 
enrichment scores for 208 BIOCARTA pathways (see Material and Methods section); pathways with the strongest correlation at each step 
of oral tumorigenesis are shown and ranked according to the Pearson’s r (F).
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mouse samples. The specificity of each gene subset for 
a given stage of oral tumorigenesis was confirmed by an 
enrichment rate calculated for each gene subset at each 
step, using the formula: |Δ GeneSet Score (Stepn-Stepn-1)| 
/ |ΔGene Set score (Tumor-Nal)|. The rates of enrichment 
score for ESG, IGS, and LGS were 80%, 97% and 78%, 
respectively (Figure 1C). In contrast, the rate of ES of the 
PGS was well distributed across different steps of oral 
tumorigenesis (24%, 29% and 47%).
In order to test the biological significance of EGS, 
IGS, LGS and PGS in the 12 mouse samples, we computed 
their enrichment score and tested their correlation with the 
enrichment score for 208 Biocarta pathways. We found 
15 pathways correlated with at least one gene set using 
a P <0.01 (see Supplementary Tables 5 and 6) (Figure 
1D). Two of the pathways involve the mitogen-activated 
protein kinases (MAPK) signaling pathways. The first one, 
“NTHI”, corresponds to an inflammatory response through 
the activation of NF-κB and p38/MAPK and was mostly 
correlated with EGS (r=0.73, P=0.0070). The second 
pathway, “TNFR1”, involves apoptosis and the JNK/
MAPK pathway, and was mostly correlated with LGS (r= 
0.79, P=0.0023). Additional pathways correlated with the 
gene subsets were immune-related. “CCR5” and “NKT” 
were mostly correlated with the IGS (r=0.81, P=0.0016 
and r=0.75, P=0.0053 respectively) while “IL4” pathway 
was highly correlated with EGS (r=0.86, P=0.0003), 
IGS (r=0.81, P=0.0014) and PGS (r=0.85, P=0.0005). 
Apoptosis was represented by “DEATH” and “FREE” 
pathways, mostly correlated with EGS (r=0.74, P=0.0061 
and r=0.81, P=0.0013 respectively) and PGS (r=0.76, 
P=0.0041 and r=0.72, P=0.0078 respectively).
The 4-NQO model derived TGS discriminates 
OSCC from normal mucosa and identifies OSCC 
with specific genomic alterations
In order to test the relevance of the 4-NQO model 
in human disease, we first determined whether the TGS 
was able to discriminate cancer vs. normal tissues in three 
datasets downloaded from public repositories, using array-
based or RNAseq expression profiles (Supplementary 
Table 7). A PCA and unsupervised hierarchical cluster 
analysis was performed using the TGS in two independent 
human datasets: GSE9844 [21] and GSE30784 [22]. Two 
main clusters were observed in GSE30784 (Figure 2A): 
the first one included no normal samples (0/45), 89% 
(151/169) of tumor samples and 59% (10/17) of dysplastic 
samples, whereas the second one included all normal 
samples (45/45), 11% (18/169) of tumor samples and 
41% (7/17) of dysplastic samples (Fisher’s exact test 
P<0.0001). Similar results were obtained in GSE9844 
(Figure 2B) with one cluster including 92% (24/26) of 
OSCC of the tongue and no normal mucosa, while the 
other one included 8% (2/26) of OSCC of the tongue and 
all the normal samples (Fisher’s exact test P<0.0001). 
We then computed the enrichment score (ES) of each 
sample for the TGS using ssGSEA and consistently 
found higher ES in cancer vs. normal mucosa samples 
in GSE30784 (Figure 2C) and GSE9844 (Figure 2D). 
Interestingly, dysplasia had intermediate scores, some of 
them overlapping with tumors, while others overlapped 
with normal mucosa (Figure 2C). These results were 
validated in a TCGA set [23] of 221 OSCC and 24 normal 
mucosa samples (Figure 2E). 4-NQO is a DNA adduct-
forming agent that serves as a surrogate of tobacco 
exposure. Interestingly, we evidenced that TGS ES scores 
were higher in smokers and drinkers (SD) compared to 
never-smokers and never drinkers (NSND) (P=0.0400) 
(Supplementary Figure 2).
We then tested whether the 4-NQO model was 
representing a subgroup of OSCC. For this purpose, 
we performed an analysis integrating gene expression, 
mutation and copy number (CN) data available for 152 
patients with OSCC in the TCGA. Although TGS ES 
was not associated with the percent of malignant cells, 
OSCC tumors were ranked according to the TGS ES 
(Figure 3). Tumors enriched for TGS were associated with 
copy number gains in 11q13.3, a region that includes in 
particular FADD, MIR548K and PPFIA13. A significant 
correlation was found between the TGS ES and FADD 
absolute CN (r=0.27, P=0.0007) (data not shown). Using 
an absolute CN > 3 to define an amplification, we showed 
that OSCC harboring FADD amplification had a significant 
higher TGS score (P=0.0039). Furthermore, higher TGS 
ES were observed in OSCC from patients with CASP8 
mutations (P=0.0595) and WT PIK3CA (P=0.0319) 
(Figure 3B, 3C, 3D).
The 4-NQO derived gene sets and their 
association with drug sensitivity patterns in vitro
We then investigated whether cell lines enriched 
for the 4-NQO derived gene sets were associated with 
specific patterns of drug sensitivity. For this, we used 
gene expression and drug sensitivity data downloaded 
from “The Genomics of Drug Sensitivity in Cancer” 
(GDSC) project [24, 25]. We selected cell lines established 
from SCC of the head and neck, esophagus and lung 
because they are included in the same cancerization field 
associated with cigarette smoking and they share common 
genomic alterations (Supplementary Table 8). EGS, IGS, 
LGS and PGS enrichment scores were computed in a 
total of 51 SCC cell lines and were correlated with the 
IC50 of 98 drugs. With a cut-off P-value of less than 0.01, 
we identified 14 drugs negatively correlated with at least 
one of the 4-NQO-derived gene sets. Most of them were 
inhibitors of the MAPK/ERK pathway and of the cell cycle 
(Figure 4A). The PGS ES was correlated with sensitivity 
to a variety of drugs. Those included an mTOR inhibitor 
(AMPK agonist) and an EGFR inhibitor (gefitinib), two 
targets that have been previously reported to prevent 
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oral cancer development in the 4-NQO model [26, 27]. 
Interestingly, all four MEK1/2 inhibitors included in the 
panel of 98 drugs were significantly correlated with the 
ES for EGS, IGS and PGS subsets (Figure 4A). Consistent 
with the results obtained in the TCGA OSCC dataset 
(Figure 3A), and using drug sensitivity and CNA data 
from CCLE [28], we observed a trend for association of 
copy number gain in 11q13.3 with increased sensitivity to 
the two MEK1/2 inhibitors (PD-0325901 and AZD6244) 
(Figure 4B) tested in 37 head and neck, esophagus and 
lung cell lines (Supplementary Table 8). Considering cell 
lines with IC50 below 8μM to be sensitive to PD-0325901 
and cell lines with IC50 above 8μM to be resistant to PD-
0325901, we found higher miR548K copy number in 
sensitive cell lines (P=0.0421) (Figure 4C).
The 4-NQO derived gene sets in human OPL and 
their association with outcome
Finally, we tested whether patients with OPL (oral 
premalignant lesions) enriched for 4-NQO derived gene 
subsets were at higher risk of developing OSCC. Gene 
expression profiles of 86 OPL collected in a prospective 
cohort of 86 patients were used (GSE26549) [11]. In this 
study, 35 patients developed an OSCC as the median 
follow-up was 7 years (95% CI [5.6-8.6]). Enrichment 
scores of these 86 OPL were computed for TGS, EGS, 
IGS, LGS, and PGS. For each gene subset, 3 groups of 
patients were defined by dividing the ES into tertiles (low, 
intermediate, high score). The Kaplan Meier analysis 
revealed a tendency of association between a poor OCFS 
Figure 2: The tumor gene set (TGS) identified in the 4-NQO model of oral tumorigenesis is relevant to human disease 
and discriminates oral squamous cell carcinoma (OSCC) from normal mucosa samples. Hierarchical clustering and principal 
component analysis (PCA) using the TGS in: a set of 45 normal oral mucosa samples, 17 oral dysplasia, 167 OSCC (GSE30784) [22]. A. 
and a set of 12 normal tongue samples and 26 Oral Tongue SCC (OTSCC) (GSE9844) [21] B. Enrichment scores (ES) were computed for 
the TGS in GSE30784 C., GSE9844 (D), and in the TCGA set of 221 OSCC and 24 normal oral mucosa samples (E). Statistical significance 
was given by a Mann Whitney test D and E. or a Kruskal-Wallis test (C). We observed a significant difference (P<0.0001) between ES of 
normal, dysplastic and tumor samples in all datasets.
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and higher ES for the EGS (Log-rank test p=0.0529) and 
PGS (Log-rank test p= 0.0495) (Figure 5). No significant 
association was found between OCFS and TGS, IGS and 
LGS (Supplementary Figure 3). (page 8)
Although univariate Cox analyses suggested a 
prognostic effect on OCFS of EGS ES (HR High vs Low 
=2.997 [1.149-7.816]; HR Intermediate vs Low=2.64 
[1.013-6.878], p=0.0681) and PGS ES (HR High vs Low 
=1.711 [0.790-3.707]; HR Intermediate vs Low=0.604 
[0.233-1.562], p=0.0681) respectively, multivariate 
analyses failed to confirm these results once adjusted on 
age and histology (Supplementary Table 9).
Overview of the results obtained across datasets
In the 4-NQO model, enrichment of the NFKB 
pathway was observed at early stages, and the activation 
of MAPK/ERK signaling pathway, was enriched at both 
early (significant enrichment of the NTHI pathway) and 
late (significant enrichment of the TNFR1 pathway) stages 
(Figure 6A). Consistently, we found that in vitro (Figure 
6B), sensitivity to inhibitors of the MAPK/ERK or NFKB 
pathways (IKK) were correlated to the ES of 4-NQO-
derived gene subsets. Similarly, IL4 pathway, that involves 
activation of the cell cycle, was found to be enriched in the 
Figure 3: An integrated analysis reveals that human oral squamous carcinomas (OSCC) enriched for the mouse tumor 
gene set (TGS) harbor specific genomic alterations. Copy number (CN) alterations, somatic mutation status and RNA sequencing 
data were analyzed for 152 patients with OSCC from the TCGA. Patients are represented by columns while specific genes are represented 
by rows. Tumors are ranked by the TGS enrichment score. The genes most frequently deleted (n=10) or amplified (n=10) in HNSCC, or 
that were found to be mutated in at least 5% of HNSCC (n=17) are shown (see Material and Methods section). Percent of malignant cells 
is shown below the TGS enrichment score A. TGS enrichment scores according to FADD amplification B. CASP8 C. and PIK3CA D. 
mutation status are shown. Statistical significance was given by a Student’s test (B) and a Mann-Whitney test (C, D). We found a higher 
TGS score in OSCC harboring FADD amplification (P=0.0039), CASP8 mutation (P=0.0595), and wild type PIK3CA (P=0.0319).
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4-NQO model, consistent with the efficacy of CDK4/6, 
CDK1, and AURKB/C inhibitors cell cycle inhibitors 
in vitro. A trend toward association of EGS and PGS 
with a poor OCFS is in favour of the clinical relevance 
of association of EGS and PGS with these biological 
pathways (Figure 6C). Finally, three pathways involving 
apoptosis were found to be enriched in the 4-NQO model, 
which was consistent with frequent FADD CN gains and 
CASP8 mutations in OSCC enriched in TGS (Figure 6D).
DISCUSSION
By analyzing the dynamics of gene expression 
changes in the 4-NQO model of oral tumorigenesis and 
by projecting those changes in various human in vitro 
and in vivo datasets, we have shown that the 4-NQO is 
a relevant mouse model for human OSCC with frequent 
CASP8 mutations and amplifications at 11q13.3, that may 
be sensitive to MEK inhibition. This work is in line with a 
recent observation of cross-species genomic conservation 
between preclinical models of HNSCC and HNSCC in 
humans [29]. We also illustrate the value of studying 
preclinical models of early tumorigenesis to help defining 
new strategies for prevention and therapy of HNSCC.
CASP8 mutations have been reported in 8-10% 
HNSCC [30–32]. They are considered as either loss-
of-function through suppression of apoptosis initiated 
by this apoptosis related-gene [30], or gain-of-function 
mutations conferring resistance to death receptor, or 
enhancing migration, invasion and tumor growth in vitro 
Figure 4: Correlation of enrichment scores for early (EGS), intermediate (IGS), late (LGS) and progressive (PGS) 
gene subsets with in vitro sensitivity to 98 drugs in established squamous cell carcinoma cell lines from the head and 
neck, esophagus and lung. A. Enrichment scores for EGS, IGS, LGS and PGS were computed in 22 head and neck, 23 esophageal 
SCC and 6 SCC of the lung and correlated with the half maximal inhibitory concentration (IC50) of 98 drugs, downloaded from the GDSC 
[24]. Most significant negative correlations are shown in red (P<0.01). Main drug target(s) are shown. B. Using data from CCLE [28], we 
show the association of Copy Number (log2 values) in 11q13 and sensitivity to 2 MEK inhibitors (AZD6244, PD-0325901), in 37 cell lines 
(5 head and neck, 15 esophageal and 17 SCC of the lung). C. Then, we compared miR548K absolute copy number between sensitive cell 
lines to PD-0325901 (IC50 <8μM) and resistant cell lines (IC50>8μM). Copy number in miR548 K (region 11q13) is higher in sensitive 
cell lines (Mann Whitney test, P=0.0421)
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[32]. CASP8 has been associated with HRAS mutations 
[31] and seems to define a subgroup of HPV-negative oral 
cancers recently identified by the presence of activating 
mutations in HRAS, inactivating CAPS8 mutations and 
wild type TP53 [33]. In our analysis, TCGA tumors 
enriched for the 4-NQO TGS were less frequently mutated 
for PIK3CA; which goes in line with the fact that PIK3CA 
mutations are found in 6-11% HNSCC, mostly in HPV-
positive and especially in pharyngeal cancers [33–35]. 
These observations suggest that CASP8 mutations may 
be involved in smoking-related tumorigenesis of the oral 
cavity, while PI3KCA may be more frequently involved in 
OSCC developing in the population of never smokers. The 
4-NQO model may be pertinent to smoking-associated 
OSCC, but is likely not relevant to OSCC affecting non-
smokers or HPV-associated oropharyngeal SCC.
Amplification in 11q13.3 was another genomic 
feature associated with OSCC enriched for the 4-NQO 
derived TGS. This region includes MIR548K, a microRNA 
recently characterized as a novel oncogene in esophageal 
squamous cell carcinomas (ESCC), a tumor entity that 
shares common risk factors and genomic alterations with 
HNSCC [36]. Depletion of MIR548K has been shown 
to suppress cellular growth and mobility, although its 
targets have not been reported. Targeting MIR548K may 
be relevant in the context of chemoprevention of tumors 
included in the same cancerization field.
The association between the enrichment mouse-
derived gene subsets in OPLs validates the relevance of 
the 4-NQO model for the study of new chemoprevention 
agents. We observed a trend in association of the EGS 
and OCFS, suggesting that the key molecular events 
occur early during oral tumorigenesis. This observation is 
consistent with our previous report of a strong association 
between gene expression changes in OPL and the risk 
of developing OSCC, beyond clinical and pathological 
variables, including histological changes [11].
Beyond risk assessment, we seek to identify new 
candidate drugs for chemoprevention. The concept of field 
cancerization refers to the effects of chronic exposure to 
smoking and alcohol in patients with or without cancer, 
with progressive onset of molecular alterations in initially 
histologically and clinically normal epithelia [37]. The 
observation of the authors was that the grossly normal 
epithelium adjacent to the invasive carcinoma frequently 
demonstrated dysplasia or carcinoma in situ. Later, 
the concept of field cancerization was supported by the 
identification of similar genetic alterations in matched 
Figure 5: Patients with oral preneoplasia enriched for the mouse early (EGS) or progressive (PGS) gene sets and 
oral cancer free survival (OCFS). Enrichment scores were computed as detailed in in 86 patients with oral preneoplasia included in 
a chemoprevention trial (GSE26549) [11] (see Material and Methods section). Higher enrichment scores for EGS (P=0.0529) and PGS 
(P=0.0495) were associated with poor oral cancer-free survival. Statistical significance was given by the log-rank test.
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dysplastic and malignant lesions from the oral cavity [4]. 
The use of molecular markers has validated the concept 
of field cancerization. Within the context of the recently 
proposed paradigm termed “reverse migration”, we tested 
the association between the enrichment of SCC cell 
lines for mouse-derived gene sets with drug sensitivity 
in order to identify new candidate drugs that may also 
benefit patients in the context of prevention [38, 39]. 
We took advantage of the resources available from the 
GDSC project. We selected SCC cell lines from various 
anatomical sites, including the head and neck, esophagus 
and lung because they were all established from tumors 
included in the cancerization field. Most significant 
correlations were observed with inhibitors of the MAPK/
ERK pathway and of the cell cycle. This was consistent 
with the results of the GSEA analysis in mouse showing 
a significant enrichment of gene sets involved in cell 
cycle and proliferation in agreement with a recent Gene 
Ontology analysis in the 4-NQO model [40]. The MAPK/
ERK pathway includes many targetable kinases [41]. 
Interestingly, the ES for the PGS was associated with 
sensitivity to number of drugs, particularly inhibitors of the 
MAPK pathway including AZD6244 (MEK1/2), CI-1040 
(MEK1/2), SL0101-1 (RSK, AURKB, PIM3), RDEA119 
Figure 6: Overview of the dynamic expression changes observed in the 4-NQO model projected in pathways pertinent 
to human oral preneoplasia (OPL) and squamous cell carcinoma (OSCC). This figure shows the coherence between main 
molecular events occurring in the 4-NQO mouse model (EGS, IGS, LGS, PGS) and those involved in human oral preneoplasia and 
OSCC. Mitogen-activated protein kinase (MAPK), apoptosis, cell cycle, and the nuclear factor NF-κB (NFKB) pathways are dysregulated 
during oral tumorigenesis and were found to be correlated (p<0.01) with one or more of mouse gene subsets as indicated by blue (PGS), 
green (EGS), red (LGS) and turquoise (IGS) arrows respectively (A). Those correlations were consistent with drug sensitivity patterns in 
established squamous cell carcinoma cell lines; corresponding targets are highlighted (yellow) within the pathways A, B. Patients whom 
OPL were enriched for the mouse EGS were at increased risk of developing OSCC (borderline statistical significance) C. OSCC enriched 
for the mouse TGS harbor genomic features (amplification region 11q13) that may be associated with increased sensitivity to MEK1/2 
inhibitors D. Abbreviations: TCGA: The Cancer Genome Atlas; GDSC: Genomics of Drug Sensitivity in Cancer; EGS: Early Gene Subset; 
IGS: Intermediate Gene Subset; LGS: Late Gene Subset; PGS: Progressive Gene Subset.
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(MEK1/ 2), PD-0325901 (MEK1/2) and gefitinib (EGFR) 
targeting members of this signaling cascade. Some may 
affect predominantly the MAPK/ERK pathway while 
others affect the MAPK/JNK pathway, confirming that 
MAPK in an important node in OSCC. Although difficult 
in the prevention setting, combination therapies may 
help addressing the challenge of acquired resistance to 
EGFR inhibition for patients with HNSCC [42]. These 
observations suggest that MEK1/2 inhibition may be 
of interest to prevent OPL malignant transformation 
or to treat OSCC harboring CASP8 mutation and/or an 
amplification at 11q13.3. Of note, our study was based on 
the analysis of a small number of mouse samples that may 
have hindered other significant pathways involved during 
oral tumorigenesis.
In conclusion, the study of the dynamics of 
molecular changes in the 4-NQO mouse model is relevant 
to identify new strategies for both the prevention of 
oral cancer development and the treatment of OSCC. In 
particular, MEK1/2 inhibition may be of interest to prevent 
the development of OSCC in patients with OPL or to treat 
patients with OSCC harboring a CASP8 mutation and/or 
amplification at 11q13.3.
MATERIALS AND METHODS
Mouse specimens
The animal protocol was approved by the University 
of Texas M.D. Anderson Cancer Center Animal Care 
and Use Committee. A total of 52 male CBA mice were 
included in the study. 4-NQO was administered in half 
of them in their drinking water at the dose of 100 μg/
mL for 8 weeks as described elsewhere [14]. Drink water 
was changed every week. Four mice treated with 4-NQO 
and four control mice were sacrificed every four weeks. 
Immediately following death, tongues were excised, 
longitudinally bisected, each half of the tongue was frozen 
on dry ice, embedded in OCT and stored at -80°C. By 
week 24, experiment was completed.
Sections of mouse tongues allowed to identify 
histologic changes associated with oral tumorigenesis 
including normal mucosa in untreated mice tongue, and 
hyperplasia, dysplasia, and tumor in 4-NQO treated mice 
tongue. Sections were 12 μm thick with a 6 μm section 
every 10 sections; all were stored at -80°C in order to 
preserve RNA quality. A half-tongue required about 
100 slides with 2 sections per slide to be fully analyzed. 
Thinner sections were fixed in 70% ethanol and stained 
with hematoxylin & eosin (H&E) for a precise mapping 
of pathological changes by a veterinary pathologist 
(A.T.). Criteria used for histologic diagnoses were similar 
to those established in human [43]. Hyperplasia was 
defined by a thickened keratinized layer, with or without 
a thickened spinous layer (acanthosis), and an absence 
of nuclear or cellular atypia. Dysplasia was defined by 
enlarged nuclei and cells, large and/or prominent nucleoli, 
increased nuclear to cytoplasmic ratio, hyperchromatic 
nuclei, dyskeratosis, increased and/or abnormal mitotic 
figures, bulbous or teardrop-shaped rete ridges, loss of 
polarity, and loss of typical epithelial cell cohesiveness. 
As proposed by Hasina et al [14], the degree of dysplasia 
was not considered as it can be difficult even in human 
preneoplasia, with a high interobserver and intraobserver 
discordance rate [14, 44]. Biological triplicates of normal 
mucosa, hyperplasia, dysplasia and tumor from 3 different 
mice were selected for subsequent steps. Only typical 
pathological diagnoses were selected from mice that 
were sacrified at different time points, in order to avoid a 
potential bias due to the biological effect of age.
In order to limit our study to changes occurring in 
epithelial cells, we used an infrared laser microdissection 
system (Arcturus PixCell II®, Life Technologies, NY, 
USA) to isolate tongue epithelial cells from the underlying 
stroma and muscle. For microdissection, the 12-μm 
sections were stained with cresyl violet (Ambion® LCM 
staining kit, Life Technologies) that allows to preserve 
RNA quality. Microdissected cells on the cap were 
solubilized using a RLT lysis buffer and were subjected to 
total RNA extraction.
Total RNA extraction was carried out using the 
RNeasy Microkit® (Qiagen) and included an on-column 
DNase digestion. The RNA integrity number (RIN) was 
measured to evaluate the quality and quantity of each RNA 
sample, using the Agilent 2100 Bioanalyzer and RNA 
6000 Pico Kit according to the manufacturer’s instructions 
(Agilent Technologies, Santa Clara, CA, USA). Aliquots of 
RNA for genome-wide transcriptome analysis were prepared 
at the time of extraction. A total of 2 ng was used for RNA 
amplification using Ovation Pico WTA System v2 (NuGEN 
Technologies, San Carlos, CA, USA). Each amplified sense 
cDNA product was fragmented and biotinylated, using 
an Encore Biotin Module according to manufacturer’s 
instructions (NuGEN Technologies). Each sample was 
hybridized onto a GeneChip Mouse Gene ST 2.0 Array 
(Affymetrix, Santa Clara, CA, USA) and imaged using the 
GeneChip Scanner 3000 7G (Affymetrix). Raw data were 
deposited in Gene Expression Omnibus (GEO) (GSE75421).
Human datasets downloaded from public 
repositories for in silico analysis
Raw data of 3 independent datasets were 
downloaded from GEO. These included a set of 26 
microdissected OSCC of the mobile tongue and 12 
matching normal mucosa (GSE9844) [21]; a set of 167 
OSCC, 17 unpaired oral dysplasia, and 45 oral cavity 
or oropharynx normal mucosa collected in patients 
who underwent a surgery for diseases other than 
cancer (GSE30784) [22]; and a set of 86 expression 
profiles from OPL biopsies collected prospectively in a 
chemoprevention trial, with a median follow-up of 7 years 
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(95% CI [5.6-8.6]) and available outcome (GSE26549) 
[11]. A detailed description of these datasets is provided 
in Supplementary Table 7.
The Cancer Genome Atlas (TCGA) was queried 
[23] (last query in July 2014). Clinical and pathological 
information from 221 HPV negative OSCC and 24 
matching normal oral mucosa were downloaded. Level 3 
RNAseqv2 data were downloaded, corresponding to gene 
read counts that were generated from the IlluminaHiSeq 
platform and normalized using MapSplice [45] to do the 
alignment and RSEM [46] to perform the quantitation. 
Then a log2 transformation was performed. Mutation and 
copy number (CN) data were downloaded from cBioPortal 
[47]. Among genes found to be significantly mutated 
by MutSig, we selected those mutated in at least 5% of 
HNSCC. The putative copy number (-2, -1, 0, 1 or 2) and 
the log2 CN given by GISTIC for 310 genes with recurrent 
CN alterations (CNAs) in HNSCC were downloaded. 
Combined mutation and CN data was available for 152 
patients with OSCC.
Gene expression raw data for 51 cell lines as 
well as drug sensitivity data (half maximal inhibitory 
concentration, IC50) for 144 drugs tested in those cell lines 
were downloaded as well from “The Genomics of Drug 
Sensitivity in Cancer” (GDSC) project [24, 25]. Combined 
expression profiles and drug sensitivity data were available 
for 98 drugs in 51 squamous cell carcinoma cell lines from 
the head and neck (n=22), the esophagus (n=23) and the 
lung (n=6). We also used drug sensitivity and copy number 
alteration data of 37 cell lines from Cancer Cell Line 
Encyplopedia [28]. Description of cell lines is provided in 
Supplementary Table 8.
Bioinformatics analysis
Data analysis was performed using the Array Studio 
software (Omicsoft Corporation) and the Bioconductor 
packages in the R language (http://www.bioconductor.
org) [48]. Raw data from microarrays were processed 
using quantile normalization and the robust multi-array 
average (RMA) algorithm and were log2 transformed 
[49]. Hierarchical cluster analysis using the Pearson 
correlation and Ward linkage method and principal 
component analysis (PCA) using the first 2 components 
were performed to provide an overview of the data and 
visualize the distribution of various samples according 
to the similarities between their expression profiles. Both 
analyses used either genome-wide expression profiles or 
specific gene sets as defined above.
Gene Set Enrichment Analysis (GSEA) was 
performed using the “pre-ranked” tool [19]. GSEA is a 
robust computational method that determines whether an 
a priori defined set of genes shows statistically significant 
differences between 2 biological states (in our case tumor 
vs. normal). GSEA aims to interpret large-scale expression 
data by identifying pathways and process. The input data 
for GSEA procedure were the following: i-a complete 
table of genes ranked according to the log2 transformed 
FC between tumor and normal mucosa, ii-a mapping file 
for identifying transcripts in the corresponding platform 
(GeneChip Mouse Gene ST 2.0 Array), and iii-a catalogue 
of functional gene sets from Molecular signature Database 
(MSigDB database v4.0 updated May 31, 2013, GSEA/
MSigDB web site v4.02 released Jan 18, 2014). A total of 
4722 curated gene sets (canonical pathway, chemical and 
genetic perturbations, BioCarta, GenMAPP, and KEGG 
gene sets) and 189 oncogenic signatures were available. 
Default parameters were used. Inclusion gene set size was 
set between 15 and 500 and the phenotype was permutated 
1,000 times.
The single-sample GSEA (ssGSEA) projection tool 
from GenePattern [50] was used to compute separate 
enrichment scores (ES) for each sample of a given dataset 
using defined gene sets i.e. TGS, IGS, LGS, PGS subsets 
and BioCarta pathways from the Molecular Signature 
Database (MSigDB database v4.0 updated May 31, 2013; 
v4.02 released Jan 18, 2014, ref 20). The gene expression 
values for a given sample are rank-normalized, and an ES 
is produced using the empirical cumulative distribution 
functions of the genes in the gene set and the remaining 
genes [19, 20]. When UP and DN versions of a gene set 
are available, a combined score was computed. A rate of 
ES was computed for early (EGS), intermediate (IGS), 
late (LGS) and progressive (PGS) gene sets at each step 
of oral tumorigenesis: from “normal to hyperplasia” (H-
>N), from “hyperplasia to dysplasia” (D->H), and from 
“dysplasia to tumor” (T->D), using the following formula:
∆
∆
−
Gene set score (Step - Step )
Gene set score (Tumor - N )
n n 1
al
Statistical analysis
Unpaired two-sided Student’s t-test or non-
parametrical Mann-Whitney test were performed to 
compare continuous data between two groups and one-
way ANOVA or Kruskal-Wallis test if more than 2 
groups. Pearson’s χ2 test or Fisher’s exact test were used 
to analyze qualitative data. The Pearson Correlation 
Coefficient (r) was also estimated to measure the strength 
of a linear association between two continuous variables. 
The r coefficient can take values from +1 (positive 
association) to -1 (negative association). A value of 0 
indicates no association.
About the analysis of the 86 samples from 
GSE26549 dataset, the median follow-up was estimated 
with the inversed Kaplan Meier method. Oral Cancer 
Free Survival (OCFS) distributions were estimated using 
the Kaplan-Meier method and compared with the Log-
Rank test between groups of patients defined by tertiles 
of gene set enrichment scores (low, intermediate and high 
score). OCFS was defined as time from first biopsy to 
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oral cancer or to the date of last follow-up (for censored 
patients). Univariate and multivariate Cox proportional 
hazard model, including age and histology, were built 
to investigate the potential association between the ES 
for TGS, EGS, IGS, LGS and PGS and oral cancer-free 
survival. All statistical tests were two-sided, and P-values 
<= 0.05 were considered to be statistically significant.
The statistical analysis was performed using 
GraphPad Prism version 6.00 (San Diego, SA) and SAS 
software version 9.3 (SAS Institute Inc, Cary, NC, USA).
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